SCHEMBL30363045

SCHEMBL30363045

CN(C)c1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 3/20 0.65
IMPDH2 P12268 7/20 0.65
IMPDH1 P20839 2/20 0.65
TGM2 P21980 1/20 0.63
P2RY1 P47900 4/20 0.62
ENPP1 P22413 2/20 0.62
P2RX1 P51575 1/20 0.62
P2RY6 Q15077 1/20 0.62
P2RY11 Q96G91 1/20 0.62
P2RX4 Q99571 1/20 0.62
TAS1R3 Q7RTX0 1/20 0.62
TAS1R1 Q7RTX1 1/20 0.62
P2RY12 Q9H244 1/20 0.61
FUT5 Q11128 1/20 0.61
KRAS P01116 2/20 0.59
RNASEL Q05823 1/20 0.59
P2RX2 Q9UBL9 1/20 0.59
NT5E P21589 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14929515 1.00 P2RX3 (0.65) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL14946399 1.00 P2RX3 (0.65) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL18574074 1.00 P2RX3 (0.65) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL16508951 0.99 IMPDH2 (0.66) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL263726 0.92 IMPDH2 (0.75) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL18289612 0.89 P2RX3 (0.68) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL18158963 0.89 P2RX3 (0.68) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL18269536 0.89 P2RX3 (0.68) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL14946391 0.88 IMPDH2 (0.64) P2RX3IMPDH2IMPDH1TGM2TAS1R3
SCHEMBL14929355 0.88 IMPDH2 (0.64) P2RX3IMPDH2IMPDH1TGM2TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4637717-A1 LIPID PARTICLE COMPOSITIONS AND METHODS OF USE THEREOF Pfizer Inc. (US) 2025-10-29 EP disclosed
EP-4412646-A1 IMMUNOGENIC LNP COMPOSITIONS AND METHODS THEREOF Pfizer Inc. (US) 2024-08-14 EP disclosed
WO-2023057930-A1 IMMUNOGENIC LNP COMPOSITIONS AND METHODS THEREOF PFIZER INC. (US) 2023-04-13 WO disclosed